Abstract:BACKGROUND & AIMS: B cells infiltrate tumors, but little is known about how they affect tumor growth and progression. microRNA15A (MIR15A or miRNA15A) and microRNA16-1 (MIR16-1 or miRNA16-1) regulate cell proliferation, apoptosis, and drug resistance. We investigated their involvement in B-cell-mediated immune suppression by colorectal tumors. METHODS: Mice with disruptions of the gene cluster that encodes MIR15A and MIR16-1 (knockout mice), and control (C57BL/B6) mice were given azoxymethane with dextran sodium sulfate (AD) to induce formation of colorectal tumors. Mice were given anti-CD20 to delete B cells, or injections of agomir to increase MIR15A and MIR16-1. Proliferation of CD8(+)T cells was measured by carboxyfluorescein-succinimidyl-ester analysis. Colon tissues were collected from mice and analyzed by flow cytometry, microRNA (miRNA) sequencing, and for cytokine production. Intestinal epithelial cells (IECs) were isolated and transfected with miRNA mimics, to identify their targets. We analyzed miRNA expression patterns and quantified B cells in colorectal cancer tissue microarrays derived from 90 patients who underwent surgical resection, from July 2006 through April 2008, in Shanghai, China; expression data were compared with clinical outcomes. RESULTS: Tumors that developed in knockout mice following administration of AD were larger and contained greater numbers of B cells than tumors that grew in control mice. Most of the B cells in the tumors were positive for immunoglobulin A (IgA(+)). IgA(+) B cells expressed high levels of immune regulatory molecules (programmed death ligand 1, interleukin 10, and transforming growth factor beta), and repressed the proliferation and activation of CD8(+) T cells. Levels of MIR15A and MIR16-1 were reduced in colon tumors from mice, compared with nontumor colon tissue. Incubation of IECs with IL17A reduced expression of MIR15A and MIR16-1. Transgenic expression of MIR15A and MIR16-1 in IECs decreased activation of NF-kappa B and STAT1 by reducing expression of I-kappaB kinases; this resulted in reduced production of chemokine (C-X-C motif) ligands 9 and 10 and decreased chemotaxis of IgA(+) B cells. Tumors in mice injected with AD and agomir grew more slowly than tumors in mice not given in agomir and contained fewer IgA(+) B cells. We found a negative correlation between levels of MIR15A and MIR16-1 and numbers of IgA(+)B cells in human colorectal tumor tissues; high levels of MIR15A and MIR16-1 and low numbers of IgA(+)B cells were associated with longer survival times of patients. CONCLUSIONS: We found increased levels of MIR15A and MIR16-1 to reduce numbers of IgA(+)B cells in colorectal tumor tissues and correlate with increased survival time of patients. In mice that lack MIR15A and MIR16-1, colon tumors grow more rapidly and contain increased numbers of IgA(+)B cells. MIR15A and MIR16-1 appear to activate signaling pathways required for B-cell-mediated immune suppression.

Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis

Butyrate-producing Eubacterium Rectale Suppresses Lymphomagenesis by Alleviating the TNF-induced TLR4/MyD88/NF-B Axis

B. ADOLESCENTIS ORCHESTRATES CD143+ CAFS TO SUPPRESS COLORECTAL TUMORIGENESIS BY WNT SIGNALLING-REGULATED GAS1

Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation

Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota

Gut microbiota modulate CD8+ T cell immunity in gastric cancer through Butyrate/GPR109A/HOPX

Suppression of Local IFN-I by Commensal Microbiota-Derived Butyrate Impairs Antitumor Effects of Ionizing Radiation

Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation

Butyrate production from high-fiber diet protects against lymphoma tumor

Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell

Integration analysis of tumor metagenome and peripheral immunity data of diffuse large-B cell lymphoma

The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma

P036 Microbiota Metabolite Butyrate Attenuates Intestinal Inflammation Through Autophagy Activation

Gut microbiota regulates AML via alternation of intestinal barrier function mediated by butyrate

The causal relationship between gut microbiota and lymphoma: a two-sample Mendelian randomization study

MicroRNAs 15A and 16–1 Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B Cells to Colorectal Tumors

Refining the relationship between gut microbiota and common hematologic malignancies: insights from a bidirectional Mendelian randomization study

Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer

Impact of Gut Microbiota on Lymphoma: New Frontiers in Cancer Research

Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients

Eubacterium rectale contributes to colorectal cancer initiation via promoting colitis